Champions Oncology Stock Performance
| CSBR Stock | USD 9.58 0.56 5.52% |
On a scale of 0 to 100, Champions Oncology holds a performance score of 6. The firm shows a Beta (market volatility) of 1.54, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Champions Oncology will likely underperform. Please check Champions Oncology's coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Champions Oncology's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Champions Oncology are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating fundamental drivers, Champions Oncology reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.52) | Five Day Return 3.9 | Year To Date Return 16.83 | Ten Year Return 22.82 | All Time Return 33.06 |
Last Split Factor 1:12 | Last Split Date 2015-08-12 |
1 | Acquisition by Ackerman Joel of 35750 shares of Champions Oncology at 5.51 subject to Rule 16b-3 | 12/31/2024 |
2 | CSBR stock hits 52-week high at 9.94 amid growth - Investing.com | 01/07/2025 |
3 | Acquisition by Sidransky David of 8045 shares of Champions Oncology at 10.1 subject to Rule 16b-3 | 01/14/2025 |
4 | Estimating The Fair Value Of Champions Oncology, Inc. | 02/04/2025 |
5 | Champions Oncology Reports Quarterly Revenue of 6.7 Million - ACCESS Newswire | 02/28/2025 |
6 | Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025 | 03/06/2025 |
7 | Champions Oncology Reports Record Quarterly Revenue of 17.0 Million Record Net Income of 4.5 Million | 03/11/2025 |
8 | Champions Oncology Third Quarter 2025 Earnings EPS US0.33 | 03/13/2025 |
| Begin Period Cash Flow | 10.1 M |
Champions |
Champions Oncology Relative Risk vs. Return Landscape
If you would invest 811.00 in Champions Oncology on December 22, 2024 and sell it today you would earn a total of 147.00 from holding Champions Oncology or generate 18.13% return on investment over 90 days. Champions Oncology is currently generating 0.416% in daily expected returns and assumes 5.4384% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Champions, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Champions Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Champions Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Champions Oncology, and traders can use it to determine the average amount a Champions Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0765
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CSBR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.44 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.42 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Champions Oncology is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Champions Oncology by adding it to a well-diversified portfolio.
Champions Oncology Fundamentals Growth
Champions Stock prices reflect investors' perceptions of the future prospects and financial health of Champions Oncology, and Champions Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Champions Stock performance.
| Return On Equity | 0.38 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 143.44 M | ||||
| Shares Outstanding | 13.83 M | ||||
| Price To Earning | 220.00 X | ||||
| Price To Book | 25.64 X | ||||
| Price To Sales | 2.34 X | ||||
| Revenue | 50.16 M | ||||
| Gross Profit | 30.22 M | ||||
| EBITDA | (5.05 M) | ||||
| Net Income | (7.28 M) | ||||
| Cash And Equivalents | 8.06 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 7.43 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.11 X | ||||
| Book Value Per Share | 0.40 X | ||||
| Cash Flow From Operations | (6.14 M) | ||||
| Earnings Per Share | 0.45 X | ||||
| Market Capitalization | 137.34 M | ||||
| Total Asset | 26.13 M | ||||
| Retained Earnings | (84.59 M) | ||||
| Working Capital | (7.9 M) | ||||
| Current Asset | 4.34 M | ||||
| Current Liabilities | 5.31 M | ||||
About Champions Oncology Performance
Assessing Champions Oncology's fundamental ratios provides investors with valuable insights into Champions Oncology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Champions Oncology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (1.44) | (1.51) | |
| Return On Assets | (0.25) | (0.26) | |
| Return On Equity | 4.40 | 4.62 |
Things to note about Champions Oncology performance evaluation
Checking the ongoing alerts about Champions Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Champions Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Champions Oncology had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 30.22 M. | |
| Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Champions Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Champions Oncology Third Quarter 2025 Earnings EPS US0.33 |
- Analyzing Champions Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Champions Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Champions Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Champions Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Champions Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Champions Oncology's stock. These opinions can provide insight into Champions Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.